Published in Braz J Microbiol on March 02, 2016
Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol (1966) 159.00
Antimicrobial peptides of multicellular organisms. Nature (2002) 23.50
Determination of minimum inhibitory concentrations. J Antimicrob Chemother (2001) 10.33
Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis (2006) 7.36
Peptide antibiotics. Lancet (1997) 6.76
Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis (2005) 6.60
Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. Proc Natl Acad Sci U S A (1978) 6.55
Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents (2005) 4.71
Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother (2006) 4.17
The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J Med Microbiol (2006) 3.27
Polymyxins revisited. Clin Microbiol Rev (2008) 3.16
The preservation of bacteria by freezing in glycerol broth. J Bacteriol (1956) 2.89
In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother (2001) 2.79
Mechanism of action of Melaleuca alternifolia (tea tree) oil on Staphylococcus aureus determined by time-kill, lysis, leakage, and salt tolerance assays and electron microscopy. Antimicrob Agents Chemother (2002) 2.38
Triggering of autolytic cell wall degradation in Escherichia coli by beta-lactam antibiotics. Antimicrob Agents Chemother (1979) 2.26
Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria. BMC Infect Dis (2005) 1.70
Colistin (coly-mycin) in resistant bacterial infections. A clinical appraisal. Arch Intern Med (1961) 1.66
Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. Antimicrob Agents Chemother (2007) 1.58
Antibacterial resistance: current problems and possible solutions. Indian J Med Sci (2005) 1.50
Basis for selectivity of cationic antimicrobial peptides for bacterial versus mammalian membranes. J Biol Chem (2005) 1.40
Colistin: an antimicrobial for the 21st century? Clin Infect Dis (2002) 1.39
Leakage of periplasmic proteins from Escherichia coli mediated by polymyxin B nonapeptide. Antimicrob Agents Chemother (1986) 1.33
Colistin and polymyxin B: a re-emergence. Indian J Crit Care Med (2009) 1.24
POLYMYXIN B AND COLISTIN. A CRITICAL COMPARISON. N Engl J Med (1964) 1.17
Polymyxins: pharmacology, pharmacokinetics, pharmacodynamics, and clinical applications. Infect Dis Clin North Am (2003) 1.15
The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature. Clin Med Res (2006) 1.14
Pandrug-resistant Pseudomonas aeruginosa among hospitalised patients: clinical features, risk-factors and outcomes. Clin Microbiol Infect (2006) 1.08
BSAC standardized disc susceptibility testing method (version 5). J Antimicrob Chemother (2006) 1.04
Efficacy of tachyplesin III, colistin, and imipenem against a multiresistant Pseudomonas aeruginosa strain. Antimicrob Agents Chemother (2007) 0.94
Interhospital transfer of pan-resistant Acinetobacter strains in Johannesburg, South Africa. Am J Infect Control (2004) 0.93
Further studies on the plasma membrane of Staphylococcus aureus. J Cell Biol (1966) 0.81